Hypoxia-inducible factor in cancer angiogenesis: Structure, regulation and clinical perspectives

Critical Reviews in Oncology/Hematology

Volumn 70, Issue 2, 2009, Pages 93-102

  Otrock, Zaher K ^a   Hatoum, Hassan A ^a   Awada, Ahmad H ^b   Ishak, Rim S ^a   Shamseddine, Ali I ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Angiogenesis; Cancer; Hypoxia inducible factor; Review

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; CYTOTOXIC AGENT; DICHLOROACETIC ACID; ECHINOMYCIN; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; NITROPRUSSIDE SODIUM; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIRAPAZAMINE; TOPOTECAN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; CONFORMATIONAL TRANSITION; DRUG MECHANISM; GENE TARGETING; HUMAN; HYPOXIA; KIDNEY CARCINOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SOLID TUMOR; TISSUE OXYGENATION; TUMOR HYPOXIA; TUMOR VASCULARIZATION;

EID: 63249123192     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.01.001     Document Type: Review

References (115)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
2. 2 tension. Proc Natl Acad Sci USA 92 (1995) 5510-5514
3. Semenza G.L. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 8 (1998) 588-594
4. Bruick R.K., and McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294 (2001) 1337-1340
5. Höpfl G., Ogunshola O., and Gassmann M. HIFs and tumors-causes and consequences. Am J Physiol Regul Integr Comp Physiol 286 (2004) R608-623
6. Goldberg M.A., Dunning S.P., and Bunn H.F. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 242 (1988) 1412-1415
7. Semenza G.L., Nejfelt M.K., Chi S.M., and Antonarakis S.E. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA 88 (1991) 5680-5684
8. Wang G.L., and Semenza G.L. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90 (1993) 4304-4308
9. Jiang B.H., Rue E., Wang G.L., Roe R., and Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271 (1996) 17771-17778
10. Michel G., Minet E., Ernest I., et al. A model for the complex between the hypoxia-inducible factor-1 (HIF-1) and its consensus DNA sequence. J Biomol Struct Dyn 18 (2000) 169-179
11. Carrero P., Okamoto K., Coumailleau P., O'Brien S., Tanaka H., and Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol Cell Biol 20 (2000) 402-415
12. Richard D.E., Berra E., Gothié E., Roux D., and Pouysségur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 274 (1999) 32631-32637
13. Hofer T., Desbaillets I., Höpfl G., Gassmann M., and Wenger R.H. Dissecting hypoxia-dependent and hypoxia-independent steps in the HIF-1alpha activation cascade: implications for HIF-1alpha gene therapy. FASEB J 15 (2001) 2715-2717
14. Aragonés J., Jones D.R., Martin S., et al. Evidence for the involvement of diacylglycerol kinase in the activation of hypoxia-inducible transcription factor 1 by low oxygen tension. J Biol Chem 276 (2001) 10548-10555
15. Huang L.E., Arany Z., Livingston D.M., and Bunn H.F. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271 (1996) 32253-32259
16. Jeong J.W., Bae M.K., Ahn M.Y., et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111 (2002) 709-720
17. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95 (1998) 7987-7992
18. Pugh C.W., O'Rourke J.F., Nagao M., Gleadle J.M., and Ratcliffe P.J. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem 272 (1997) 11205-11214
19. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15 (1999) 551-578
20. Ema M., Taya S., Yokotani N., Sogawa K., Matsuda Y., and Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 94 (1997) 4273-4278
21. Tian H., McKnight S.L., and Russell D.W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11 (1997) 72-82
22. Tian H., Hammer R.E., Matsumoto A.M., Russell D.W., and McKnight S.L. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12 (1998) 3320-3324
23. Makino Y., Kanopka A., Wilson W.J., Tanaka H., and Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 277 (2002) 32405-32408
24. Gu Y.Z., Moran S.M., Hogenesch J.B., Wartman L., and Bradfield C.A. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 7 (1998) 205-213
25. Salceda S., and Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272 (1997) 22642-22647
26. Kallio P.J., Pongratz I., Gradin K., McGuire J., and Poellinger L. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci USA 94 (1997) 5667-5672
27. Lando D., Peet D.J., Whelan D.A., Gorman J.J., and Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295 (2002) 858-861
28. Perkins G.R., Marshall C.J., and Collins M.K. The role of MAP kinase in interleukin-3 stimulation of proliferation. Blood 87 (1996) 3669-3675
29. Dameron K.M., Volpert O.V., Tainsky M.A., and Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265 (1994) 1582-1584
30. Bouvet M., Ellis L.M., Nishizaki M., et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 58 (1998) 2288-2292
31. Blancher C., Moore J.W., Robertson N., and Harris A.L. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 61 (2001) 7349-7355
32. Zundel W., Schindler C., Haas-Kogan D., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14 (2000) 391-396
33. Jiang B.H., Jiang G., Zheng J.Z., Lu Z., Hunter T., and Vogt P.K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12 (2001) 363-369
34. Zhong H., Chiles K., Feldser D., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
35. Krishnamachary B., Berg-Dixon S., Kelly B., et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63 (2003) 1138-1143
36. Treins C., Giorgetti-Peraldi S., Murdaca J., Semenza G.L., and Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 277 (2002) 27975-27981
37. Laughner E., Taghavi P., Chiles K., Mahon P.C., and Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21 (2001) 3995-4004
38. Stiehl D.P., Jelkmann W., Wenger R.H., and Hellwig-Bürgel T. Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett 512 (2002) 157-162
39. Brahimi-Horn C., Mazure N., and Pouysségur J. Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell Signal 17 (2005) 1-9
40. Srinivas V., Zhang L.P., Zhu X.H., and Caro J. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins. Biochem Biophys Res Commun 260 (1999) 557-561
41. Masson N., Willam C., Maxwell P.H., Pugh C.W., and Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 20 (2001) 5197-5206
42. Masson N., and Ratcliffe P.J. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels. J Cell Sci 116 (2003) 3041-3049
43. Epstein A.C., Gleadle J.M., McNeill L.A., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
44. Huang J., Zhao Q., Mooney S.M., and Lee F.S. Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J Biol Chem 277 (2002) 39792-39800
45. Berra E., Benizri E., Ginouvès A., Volmat V., Roux D., and Pouysségur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22 (2003) 4082-4090
46. 2 sensing. Science 292 (2001) 464-468
47. 2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
48. Krek W. VHL takes HIF's breath away. Nat Cell Biol 2 (2000) E121-E123
49. Jung Y.J., Isaacs J.S., Lee S., Trepel J., and Neckers L. Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein. J Biol Chem 278 (2003) 7445-7452
50. Cockman M.E., Masson N., Mole D.R., et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275 (2000) 25733-25741
51. Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., and Conaway J.W. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97 (2000) 10430-10435
52. Krieg M., Haas R., Brauch H., Acker T., Flamme I., and Plate K.H. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19 (2000) 5435-5443
53. Ohh M., Park C.W., Ivan M., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2 (2000) 423-427
54. Tanimoto K., Makino Y., Pereira T., and Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19 (2000) 4298-4309
55. Kim M.S., Kwon H.J., Lee Y.M., et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7 (2001) 437-443
56. Sang N., Fang J., Srinivas V., Leshchinsky I., and Caro J. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol 22 (2002) 2984-2992
57. Dames S.A., Martinez-Yamout M., De Guzman R.N., Dyson H.J., and Wright P.E. Structural basis for Hif-1 alpha/CBP recognition in the cellular hypoxic response. Proc Natl Acad Sci USA 99 (2002) 5271-5276
58. Freedman S.J., Sun Z.Y., Poy F., et al. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci USA 99 (2002) 5367-5372
59. Hewitson K.S., McNeill L.A., Riordan M.V., et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 277 (2002) 26351-26355
60. Mahon P.C., Hirota K., and Semenza G.L. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15 (2001) 2675-2686
61. Metzen E., Berchner-Pfannschmidt U., Stengel P., et al. Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. J Cell Sci 116 (2003) 1319-1326
62. Chan D.A., Sutphin P.D., Denko N.C., and Giaccia A.J. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J Biol Chem 277 (2002) 40112-40117
63. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., and Neckers L.M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277 (2002) 29936-29944
64. Katschinski D.M., Le L., Heinrich D., et al. Heat induction of the unphosphorylated form of hypoxia-inducible factor-1alpha is dependent on heat shock protein-90 activity. J Biol Chem 277 (2002) 9262-9267
65. Sodhi A., Montaner S., Patel V., et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 60 (2000) 4873-4880
66. Minet E., Michel G., Mottet D., Raes M., and Michiels C. Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation. Free Radic Biol Med 31 (2001) 847-855
67. Hur E., Chang K.Y., Lee E., Lee S.K., and Park H. Mitogen-activated protein kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha. Mol Pharmacol 59 (2001) 1216-1224
68. Suzuki H., Tomida A., and Tsuruo T. Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 20 (2001) 5779-5788
69. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 (1996) 4604-4613
70. Olsson A.K., Dimberg A., Kreuger J., and Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 7 (2006) 359-371
71. Jensen R.L., Ragel B.T., Whang K., and Gillespie D. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol 78 (2006) 233-247
72. Bos R., Zhong H., Hanrahan C.F., et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93 (2001) 309-314
73. Maxwell P.H., Dachs G.U., Gleadle J.M., et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94 (1997) 8104-8109
74. Tang N., Wang L., Esko J., et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6 (2004) 485-495
75. Das B., Yeger H., Tsuchida R., et al. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res 65 (2005) 7267-7275
76. Gerber H.P., Condorelli F., Park J., and Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 272 (1997) 23659-23667
77. Ryan H.E., Lo J., and Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17 (1998) 3005-3015
78. Burri P., Djonov V., Aebersold D.M., et al. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56 (2003) 494-501
79. Schindl M., Schoppmann S.F., Samonigg H., et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8 (2002) 1831-1837
80. Birner P., Schindl M., Obermair A., Breitenecker G., and Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7 (2001) 1661-1668
81. Sivridis E., Giatromanolaki A., Gatter K.C., Harris A.L., Koukourakis M.I., Tumor, and Angiogenesis Research Group. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95 (2002) 1055-1063
82. Takahashi R., Tanaka S., Hiyama T., et al. Hypoxia-inducible factor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol Rep 10 (2003) 797-802
83. Koukourakis M.I., Giatromanolaki A., Skarlatos J., et al. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 61 (2001) 1830-1832
84. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7 (2001) 3399-3403
85. Giatromanolaki A., Koukourakis M.I., Sivridis E., et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85 (2001) 881-890
86. Beasley N.J., Leek R., Alam M., et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62 (2002) 2493-2497
87. Volm M., and Koomägi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 20 (2000) 1527-1533
88. Melillo G. HIF-1: a target for cancer, ischemia and inflammation-too good to be true?. Cell Cycle 3 (2004) 154-155
89. Yeo E.J., Chun Y.S., and Park J.W. New anticancer strategies targeting HIF-1. Biochem Pharmacol 68 (2004) 1061-1069
90. Giaccia A., Siim B.G., and Johnson R.S. HIF-1 as a target for drug development. Nat Rev Drug Discov 2 (2003) 803-811
91. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
92. Brown J.M., and Siim B.G. Hypoxia-specific cytotoxins in cancer therapy. Semin Radiat Oncol 6 (1996) 22-36
93. Post D.E., Devi N.S., Li Z., et al. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 10 (2004) 8603-8612
94. Post D.E., and Van Meir E.G. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 22 (2003) 2065-2072
95. Birner P., Schindl M., Obermair A., et al. Lymphatic microvessel density in epithelial ovarian cancer: its impact on prognosis. Anticancer Res 20 (2000) 2981-2985
96. Bos R., van der Groep P., Greijer A.E., et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97 (2003) 1573-1581
97. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., and Semenza G.L. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88 (2000) 2606-2618
98. Belozerov V.E., and Van Meir E.G. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 16 (2005) 901-909
99. Welsh S., Williams R., Kirkpatrick L., Paine-Murrieta G., and Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 3 (2004) 233-244
100. Koh M.Y., Spivak-Kroizman T., Venturini S., et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 7 (2008) 90-100
101. Welsh S.J., and Powis G. Hypoxia inducible factor as a cancer drug target. Curr Cancer Drug Targets 3 (2003) 391-405
102. Kaelin Jr. W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2 (2002) 673-682
103. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
104. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
105. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
106. Hudson C.C., Liu M., Chiang G.G., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22 (2002) 7004-7014
107. Hudes G., Carducci M., Tomczak P., et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
108. Motzer R.J., Escudier B., Oudard S., et al. RAD001 vs. placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter Phase-III study. J Clin Oncol 26 (2008) [Suppl.; abstr LBA5026]
109. Papandreou I., Cairns R.A., Fontana L., Lim A.L., and Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3 (2006) 187-197
110. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4 (2004) 437-447
111. Cairns R.A., Papandreou I., Sutphin P.D., and Denko N.C. Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci USA 104 (2007) 9445-9450
112. Takabuchi S., Hirota K., Nishi K., et al. The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway. Biochem Biophys Res Commun 324 (2004) 417-423
113. Melillo G., and Semenza G.L. Meeting report: exploiting the tumor microenvironment for therapeutics. Cancer Res 66 (2006) 4558-4560
114. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H., and Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64 (2004) 1475-1482
115. Beppu K., Nakamura K., Linehan W.M., Rapisarda A., and Thiele C.J. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res 65 (2005) 4775-4781